Literature DB >> 11964123

The role of glycosylation in protein antigenic properties.

E Lisowska1.   

Abstract

Glycosylation of proteins is a common event and contributes to protein antigenic properties. Most data have been obtained from model studies on glycoprotens with well-defined structure or synthetic glycopeptides and their respective monoclonal antibodies. Antibodies raised against glycoprotein antigens may be specific for their carbohydrate units which are recognized irrespective of the protein carrier (carbohydrate epitopes), or in the context of the adjacent amino acid residues (glycopeptidic epitopes). Conformation or proper exposure of peptidic epitopes of glycoproteins is also frequently modulated by glycosylation due to intramolecular carbohydrate-protein interactions. The effects of glycosylation are broad: glycosylation may 'inactivate' the peptidic epitope or may be required for its reactivity with the antibody, depending on the structure of the antigenic site and antibody fine specificity. Evidence is increasing that similar effects of glycosylation pertain to T cell-dependent cellular immune responses. Glycosylated peptides can be bound and presented by MHC class I or II molecules and elicit glycopeptide-specific T cell clones.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964123     DOI: 10.1007/s00018-002-8437-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  21 in total

Review 1.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

2.  The role of anti-CCD antibodies in grape allergy diagnosis.

Authors:  Reza Falak; Mojtaba Sankian; Hanieh Ketabdar; Malihe Moghadam; Abdol-Reza Varasteh
Journal:  Rep Biochem Mol Biol       Date:  2013-04

3.  Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice.

Authors:  Dibyadyuti Datta; Geetha P Bansal; Rajesh Kumar; Barry Ellefsen; Drew Hannaman; Nirbhay Kumar
Journal:  Clin Vaccine Immunol       Date:  2015-07-01

4.  Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals.

Authors:  Ayelet Zlotogorski-Hurvitz; Dan Dayan; Gavriel Chaushu; Tuula Salo; Marilena Vered
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-27       Impact factor: 4.553

Review 5.  Erythropoietin biosimilars currently available in hematology-oncology.

Authors:  Didier Kamioner
Journal:  Target Oncol       Date:  2012-01-18       Impact factor: 4.493

6.  Temporal lineage dynamics of the ORF5 gene of porcine reproductive and respiratory syndrome virus in Korea in 2014-2019.

Authors:  Seung-Chai Kim; Chang-Gi Jeong; Gyeong-Seo Park; Ji-Young Park; Hye-Young Jeoung; Go-Eun Shin; Mi-Kyeong Ko; Seoung-Hee Kim; Kyoung-Ki Lee; Won-Il Kim
Journal:  Arch Virol       Date:  2021-08-10       Impact factor: 2.574

Review 7.  Glycosylation is a key in SARS-CoV-2 infection.

Authors:  Celso A Reis; Rudolf Tauber; Véronique Blanchard
Journal:  J Mol Med (Berl)       Date:  2021-05-22       Impact factor: 4.599

8.  Identification of linear epitopes on the flagellar proteins of Clostridioides difficile.

Authors:  A Razim; K Pacyga; P Naporowski; D Martynowski; A Szuba; A Gamian; S Górska
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

9.  Cell surface-specific N-glycan profiling in breast cancer.

Authors:  Xia Liu; Huan Nie; Yubao Zhang; Yuanfei Yao; Alaiyi Maitikabili; Youpeng Qu; Shuliang Shi; Cuiying Chen; Yu Li
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

10.  Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples.

Authors:  Paul J Boersema; Tamar Geiger; Jacek R Wisniewski; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2012-10-22       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.